This impressive FTSE small-cap is on my list of ones to watch. Here’s what I’d do now

Jabran Khan delves deeper into a FTSE small cap he believes will begin to soar in the future and why he thinks it may be worth buying cheaply right now.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

I like to think of myself as a savvy investor. And for me, part of building a diverse portfolio involves looking for the next big thing on the FTSE AIM index.

Yourgene Health Plc (LSE:YGEN) is on my ‘ones to watch list’ list. It’s a genetic testing firm that produces non-invasive products for male fertility and prenatal screening for cystic fibrosis and other genetic disorders. In addition, YGEN is planning to expand into genetic testing for cancer detection and prevention. YGEN has also joined the Covid-19-related products market with its own testing solution.

FTSE AIM opportunity

YGEN has been listed on the FTSE AIM for six years and has been steadily increasing its footprint. It has established a commercial presence in the UK, Europe, the Middle East, Africa and Asia.

YGEN does relies on commercial partnerships with bigger DNA testing firms out there but I do not see this as a drawback. Sometimes smaller companies will bring fresh ideas and proprietary knowledge to the table. Larger firms then utilise their own infrastructure and reach and both parties benefit.

I always take notice of companies who undergo acquisitions to grow, especially into new territories such as the US. Yourgene acquired Elucigene in April 2019 and launched its first oncology product. I believe this is a statement of ambition and will help it to reach new heights.

As I write this, shares in YGEN can be picked up for a very modest 17p per share. Just before the market crash that rocked the whole FTSE index, shares were trading very close to a similar level of 17p. The crash did cause a small dip in price and shares could be purchased at just 10p. Even at current prices, I consider this a bargain with very little risk involved.

Recent performance

On Monday, YGEN released a half-year trading update for the six months ending 30 September 2020. There were several positive takeaways from this report. Revenue increased 5% compared to the same period last year. The UK and Europe each saw a healthy increase of 40% and 80% respectively. This helped offset a reduction in revenue for the rest of the world. This was to be expected as many firms across the FTSE reported difficulties due to the market crash. YGEN also saw revenues for its Covid-19 testing solution begin to increase and the forecast for the second half of the year is positive.

In addition to the financials, YGEN raised £15m of funds to complete a new acquisition in the form of Canadian firm Coastal Genomics, which I believe will further its reach in the North American market.

My verdict

I really like the look of Yourgene even though it is just a £128m market cap business. It is making good headway with its footprint and is attempting to gain a share of a multi-billion pound industry. It is regularly acquiring smaller firms and amalgamating them into its operation to enhance its offering. Also, YGEN is showing growth in respect of revenue and has joined the potentially lucrative Covid-19 product market.

At its current price, I believe YGEN represents a bargain, albeit with a small amount of risk involved. I like picking up FTSE small-caps when they have potential such as this, as it helps diversify my portfolio.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Jabran Khan has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

5 steps to start buying shares with under £500

Learn how this writer would start buying shares with a few hundred pounds in a handful of steps, if he…

Read more »

Young happy white woman loading groceries into the back of her car
Investing Articles

The FTSE 100 offers some great bargains. Is this one?

Our writer digs into one FTSE 100 share that has had a rough 2024 to date, ahead of its interim…

Read more »

Smiling white woman holding iPhone with Airpods in ear
Investing Articles

£9,000 of savings? Here’s my 3-step approach to aim for £1,794 in passive income

Christopher Ruane walks through the practical steps he would take to try and turn £9,000 into a sizeable passive income…

Read more »

Group of young friends toasting each other with beers in a pub
Investing Articles

I’d buy 29,412 shares of this UK dividend stock for £150 a month in passive income

Insiders have been buying this dividend stock, which offers an 8.5% yield. Roland Head explains why he’d choose the shares…

Read more »

Red briefcase with the words Budget HM Treasury embossed in gold
Investing Articles

Could the new UK budget spell growth for these 6 FTSE stocks? I think so!

Mark David Hartley considers six UK stocks that could enjoy growth off the back of new measures announced in the…

Read more »

Investing Articles

With a 6.6% yield, is now the right time to add this income stock to my ISA?

Our writer’s looking to boost his Stocks and Shares ISA. With this in mind, he’s debating whether to buy a…

Read more »

Dividend Shares

This blue-chip FTSE stock just fell 12.5% in a day. Is it time to consider buying?

Smith & Nephew is a well-known, blue-chip FTSE stock with a decent dividend yield. And its share price just dropped…

Read more »

Investing Articles

At 72p, the Vodafone share price looks to be at least 33% undervalued to me

Our writer looks at a number of valuation measures to determine whether the Vodafone share price reflects the fair value…

Read more »